Comparison of Growth Factor Releases and Degradation Rates of Membranes Obtained From A-PRF+, L-PRF, and Alb-PRF (PRF)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Platelet-rich fibrin products have become increasingly popular in regenerative medicine because they provide a fibrin scaffold capable of releasing multiple growth factors over time. However, differences in centrifugation protocols and preparation techniques may significantly affect their biological properties.
Albumin-PRF is a recently introduced modification that combines heat-denatured plasma proteins with injectable PRF to increase scaffold stability and prolong growth factor release.
This study will compare Alb-PRF, A-PRF+, and L-PRF prepared from the same healthy volunteers. Cumulative release of VEGF, PDGF-BB, and TGF-β1 will be evaluated on Days 1, 3, 5, and 7 using ELISA. Resistance to enzymatic degradation will be assessed by measuring delta D-dimer concentrations following trypsin-EDTA exposure. The results are expected to improve understanding of the biological performance of different PRF formulations.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
İzmir
-
Izmir, İzmir, Tyrkiet (Türkiye), 35620
- Izmir Katip Celebi University Faculty of Dentistry
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Healthy volunteers aged 18 to 40 years
- Male or female
- Able and willing to provide written informed consent
- Non-smokers
- No history of systemic disease
- No regular medication use
- No use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months
Exclusion Criteria:
- Age younger than 18 years or older than 40 years
- Smoking
- Pregnancy or breastfeeding
- History of any systemic disease
- Regular medication use
- Use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months
- Refusal or inability to provide written informed consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Ikke-randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Albumin-Platelet Rich Fibrin (Alb-PRF)
Blood samples obtained from healthy volunteers were processed using the Albumin-Platelet Rich Fibrin (Alb-PRF) protocol.
Growth factor release and resistance to enzymatic degradation were evaluated under standardized laboratory conditions.
|
Autologous Albumin-Platelet Rich Fibrin prepared from peripheral venous blood using the Alb-PRF protocol for evaluation of growth factor release and enzymatic degradation.
|
|
Eksperimentel: Leukocyte-Platelet Rich Fibrin (L-PRF)
Blood samples obtained from healthy volunteers were processed using the Leukocyte-Platelet Rich Fibrin (L-PRF) protocol.
Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Advanced Platelet-Rich Fibrin+ (A-PRF+).
|
Autologous Leukocyte-Platelet Rich Fibrin prepared from peripheral venous blood using the L-PRF protocol for evaluation of growth factor release and enzymatic degradation.
|
|
Eksperimentel: Advanced - Platelet Rich Fibrin+ (A-PRF+)
Blood samples obtained from healthy volunteers were processed using the Advanced Platelet-Rich Fibrin+ (A-PRF+) protocol.
Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Leukocyte-Platelet Rich Fibrin (L-PRF) .
|
Autologous Advanced Platelet-Rich Fibrin+ prepared from peripheral venous blood using the A-PRF+ protocol for evaluation of growth factor release and enzymatic degradation.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
VEGF concentration released from PRF membranes
Tidsramme: Day 1, Day 3, Day 5, and Day 7
|
Quantitative assessment of VEGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
|
Day 1, Day 3, Day 5, and Day 7
|
|
PDGF concentration released from PRF membranes
Tidsramme: Day 1, Day 3, Day 5, and Day 7
|
Quantitative assessment of PDGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
|
Day 1, Day 3, Day 5, and Day 7
|
|
TGF-B concentration released from PRF membranes
Tidsramme: Day 1, Day 3, Day 5, and Day 7
|
Quantitative assessment of TGF-B released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
|
Day 1, Day 3, Day 5, and Day 7
|
|
Resistance to enzymatic degradation
Tidsramme: 60 minutes and 120 minutes
|
Assessment of fibrin degradation by measuring D-dimer levels after enzymatic digestion of PRF preparations.
|
60 minutes and 120 minutes
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2025-TDU-DİŞF-0014
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .